PALI

Palisade Bio, Inc. [PALI] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PALI Stock Summary

Top 10 Correlated ETFs

PALI

Top 10 Correlated Stocks

PALI

In the News

PALI Financial details

Company Rating
-
Market Cap
49.98M
Income
-11.82M
Revenue
250K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
21 Mar 2024
P/E
-0.34
Forward P/E
-
PEG
0.04
P/S
20.03
P/B
0.28
P/C
-
P/FCF
-0.43
Quick Ratio
5.83
Current Ratio
6.14
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-4.57
EPS next Y
-
EPS next Q
-
EPS this Y
-90.03%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-46.28%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-7.55%
-
-
-
-
SMA20
-35.63%
SMA50
-52.09%
SMA100
-71.55%
Inst Own
-
Inst Trans
-
ROA
-69%
ROE
-84%
ROC
-0.95%
Gross Margin
100%
Oper. Margin
-5506%
Profit Margin
-4728%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.82-36.6
52W High
-97.38%
52W Low
-68.56%
RSI
23.99
Rel Volume
0.44
Avg Volume
197.7K
Volume
86.06K
Perf Week
-16.53%
Perf Month
-58.63%
Perf Quarter
-73.43%
Perf Half Y
-73.65%
-
-
-
-
Beta
1.575
-
-
Volatility
0.03%, 0.29%
Prev Close
-3.76%
Price
0.9432
Change
-6.61%

Something similar

Top by Market Cap
FXAIX
EMBASSY.NS
GOOGL
MSFT
BRK-B
Top Correlated ETFs
YANG
FXP
YXI
EEV
GLL
Top Correlated Stocks
CETX
WW
ANNX
WNC
HBIO
Similar Market Cap
ZSRL.DE
HLFNX
JUVF
8079.HK
DIA.L

Company Profile

Healthcare Biotechnology
  • Volume Average 197.7K
  • Market Capitalization 49.98M
  • Employee 12
  • CEO Mr. J. D. Finley
  • Headquarters Carlsbad,CA,US
  • IPO Date 2007-03-30
  • Website https://www.palisadebio.com

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from reduced blood flow to the intestine, infections, or due to surgery. The company was founded in 2005 and is headquartered in Carlsbad, California.